All for Joomla All for Webmasters

Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID‐19

Rate this item
(0 votes)

Abstract:

Background

Coronavirus disease‐2019 (COVID‐19) is a recognized prothrombotic state. Patients hospitalized with active cancer are predisposed to thrombosis but whether active cancer further amplifies thrombotic risk with COVID‐19 is not known.

Objectives

To evaluate cumulative incidences of thrombotic and hemorrhagic events in hospitalized COVID‐19 patients with and without active cancer at 28 days.

Methods

A retrospective cohort analysis of consecutive adults hospitalized with COVID‐19 was performed. Active cancer required cancer‐directed therapy within previous 6 months. The cumulative incidences of thrombosis or hemorrhage were estimated considering death as a competing risk.

Results

Patients without cancer (n = 353) and active cancer (n = 45) were comparable in terms of age, sex, antibiotics administered, length of hospitalization, and critical care. The most common malignancies were lymphoid (17.8%), gastrointestinal (15.6%), lung (13.3%), and genitourinary (13.3%). At day 28, the cumulative incidence of thrombotic events was 18.2% (95% confidence interval [CI], 10.2%‐27.9%) in the non‐cancer cohort and 14.2% (95% CI, 4.7%‐28.7%) in the cancer cohort. The cumulative incidence of major and fatal bleeding at day 28 was 20.8% (95% CI, 12.1%‐31.0%) in the non‐cancer group and 19.5% (95% CI, 5.5%‐39.8%) in the cancer cohort. Three patients experienced fatal bleeds, all of whom were in the non‐cancer cohort. Survival was significantly shorter in the group with active cancer (P = .038).

Conclusions

We observed a similarly high incidence of thrombosis and bleeding among patients admitted with COVID‐19 with or without active cancer.

Read 169 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection